India's first indigenous dengue vaccine DengiAll may arrive by 2027
ICMR plans to roll out India's first indigenous dengue vaccine, DengiAll, by 2027 if clinical trials succeed. Developed by Panacea Biotec, the single-dose, live-attenuated vaccine is designed to work against all four dengue serotypes, DENV-1 to DENV-4. ICMR Director General Rajiv Bahl, speaking in Kolkata, said the Phase 3 trial is running across 20 institutes in India with more than 13,000 volunteers, and results could be unblinded by the end of next year. India reported around 1.13 lakh dengue cases and nearly 100 deaths in 2025.
Source
Firstpost — India · read the original report ↗
Desk check · some claims need care
What the desk checked (5)
- ICMR plans to roll out DengiAll by 2027 if clinical trials succeed — Attributed to ICMR in source; conditional and forward-looking, not a confirmed approval date.
- Phase 3 trial runs across 20 institutes with more than 13,000 volunteers — Quoted from ICMR Director General Rajiv Bahl via News18, as cited in the source.
- Results may be unblinded by the end of next year — Attributed to Bahl speaking in Kolkata; expectation, not a fixed schedule.
- Panacea Biotec developed the single-dose, live-attenuated tetravalent vaccine — Figure and description appear in source, citing a clinical update; no document link given.
- India reported about 1.13 lakh dengue cases and nearly 100 deaths in 2025 — Source cites official data without naming the agency; source itself notes possible underreporting.
Analysts’ view opinion
DengiAll is, for now, a research-capacity milestone rather than a public health policy win. The ICMR–Panacea Biotec arrangement, with a Phase 3 trial across 20 institutes and more than 13,000 volunteers, reads as a continuation of the public-private vaccine development model India leaned on during the Covid years. The harder policy questions — who gets it, at what age, at what price, and whether it enters the national immunisation programme — are simply not addressed in this story. The 2027 timeline is a conditional target that hinges on trial results and regulatory assessment.
- The single-dose design is a significant policy advantage: it simplifies logistics and reduces dropout compared with multi-dose regimens, a persistent weak point in large immunisation drives.
- The tetravalent ambition matters because immunity to one serotype does not protect against the others, so partial protection would be policy-inadequate.
- India's 1.13 lakh cases and nearly 100 deaths in 2025 mark a decline from 2023 and 2024, but experts caution the true burden is likely higher due to underreporting — meaning the data base for prioritisation decisions is itself shaky.
- Even a successful vaccine complements rather than replaces vector control, urban sanitation and surveillance, since rapid urbanisation and changing climate patterns are the underlying drivers.
- Pricing, manufacturing capacity, state-level distribution and target age cohorts need to be worked out in parallel, or post-approval policy decisions themselves become the bottleneck.
What to watch — Watch the unblinding of trial results expected by the end of next year and the regulatory assessment that follows, plus any signal on whether the vaccine is routed through the national immunisation programme or left largely to the private market.
Safety and efficacy remain unproven, and the story establishes nothing about price, target population or inclusion in any government programme — nor is the 2027 date guaranteed.
Deep dive
Research brief · 8 facts · 5 dates · exam-readyThe brief
Context
Dengue, spread by infected Aedes mosquitoes, is endemic in India and surges every monsoon, straining hospitals. The virus has four serotypes (DENV-1 to DENV-4) and immunity to one does not protect against the others, which makes a tetravalent vaccine essential. The Indian Council of Medical Research (ICMR) is now working with Panacea Biotec on DengiAll, India's first indigenous dengue vaccine, a single-dose live-attenuated formulation. If Phase 3 clinical trials succeed, the vaccine could be available for authorised public use by 2027.
Key facts
- ICMR plans to roll out DengiAll, India's first indigenous dengue vaccine, for authorised public use by 2027 if clinical trials succeed.
- DengiAll is developed by Panacea Biotec as a single-dose, live-attenuated vaccine designed to trigger neutralising antibodies against all four dengue strains.
- Dengue exists in four serotypes: DENV-1, DENV-2, DENV-3 and DENV-4; immunity to one does not ensure protection against the others.
- ICMR Director General Rajiv Bahl said the Phase 3 trial is being conducted across 20 institutes in India with more than 13,000 volunteers.
- Bahl, speaking in Kolkata, said the trial has completed almost a year of follow-up and researchers hope to unblind results by the end of next year.
- India reported around 1.13 lakh dengue cases and nearly 100 deaths in 2025 according to official data, though experts warn the real burden may be higher due to underreporting.
- The 2025 figure marks a decline compared with previous years such as 2023 and 2024, but dengue remains endemic with infections peaking during and after the monsoon.
- A single-dose shot, if approved, could streamline vaccination logistics and improve compliance compared with multi-dose vaccines.
Timeline
- 2023 and 2024Dengue case numbers in India were higher than in 2025, per the source's comparison.
- 2025India reports around 1.13 lakh dengue cases and nearly 100 deaths, according to official data.
- As stated by ICMR DG Rajiv BahlPhase 3 trial across 20 institutes with more than 13,000 volunteers completes almost a year of follow-up.
- End of next year (as per Bahl's statement)Researchers hope to unblind the Phase 3 study results.
- By 2027DengiAll could be available for authorised public use if trials succeed.
Who has a stake
- Indian Council of Medical Research (ICMR) — Leading the Phase 3 trial and the planned rollout; its DG Rajiv Bahl is the public voice on timelines.
- Panacea Biotec — Developer of DengiAll as a single-dose live-attenuated tetravalent formulation; commercial and scientific credibility at stake.
- The 20 participating institutes and 13,000-plus trial volunteers — Carry out and participate in the follow-up on which safety and efficacy conclusions depend.
- Drug regulators — Final safety, efficacy and appropriate-use decisions rest on clinical-trial and regulatory assessment before approval.
- Public health systems and patients — Face annual monsoon surges of dengue that strain hospitals; a vaccine would complement mosquito control.
Why it matters
Dengue remains endemic in India with roughly 1.13 lakh reported cases and nearly 100 deaths in 2025, and experts say underreporting means the true burden is higher. Because four serotypes circulate and infection with one does not protect against the rest, a tetravalent, single-dose indigenous vaccine could add a preventive tool alongside mosquito control. Domestic development also matters for affordability and supply in a country where cases peak every monsoon.
UPSC angle
Prelims pointers
- DengiAll: India's first indigenous dengue vaccine, developed by Panacea Biotec; single-dose, live-attenuated.
- Dengue serotypes: DENV-1, DENV-2, DENV-3, DENV-4; a tetravalent vaccine targets all four.
- Dengue is a mosquito-borne viral infection transmitted primarily by infected Aedes mosquitoes.
- ICMR Director General: Rajiv Bahl; announced trial details in Kolkata.
- Phase 3 trial: 20 institutes in India, more than 13,000 volunteers; unblinding expected by end of next year.
- India's 2025 dengue burden: about 1.13 lakh cases and nearly 100 deaths (official data).
Mains framing
India's dengue burden is driven by rapid urbanisation, changing climate patterns and the expanding reach of mosquito vectors, with cases peaking during and after the monsoon and official 2025 figures of about 1.13 lakh cases and nearly 100 deaths likely understating the true load. The scientific difficulty is intrinsic to the disease: four serotypes (DENV-1 to DENV-4) circulate and immunity to one does not confer protection against the others, so any useful vaccine must be tetravalent. DengiAll, a single-dose live-attenuated candidate from Panacea Biotec now in Phase 3 across 20 Indian institutes with more than 13,000 volunteers, addresses this by aiming to trigger neutralising antibodies against all four strains, and its single-dose format could simplify logistics and improve compliance. The implications are both epidemiological and systemic: a homegrown vaccine reduces dependence on imports and could ease seasonal pressure on hospitals. The way forward, as the source itself stresses, is rigorous completion of follow-up, unblinding of results and regulatory assessment of safety, efficacy and appropriate use, with vaccination positioned as a complement to, not a replacement for, mosquito control and broader public health measures, including better surveillance to correct underreporting.
Key terms
- DengiAll
- India's first indigenous dengue vaccine candidate, a single-dose live-attenuated formulation developed by Panacea Biotec.
- ICMR
- Indian Council of Medical Research, the apex body conducting the Phase 3 trial and planning the vaccine rollout.
- Tetravalent vaccine
- A vaccine designed to protect against all four dengue serotypes, DENV-1 to DENV-4, at once.
- Live-attenuated vaccine
- A vaccine using a weakened form of the virus to trigger neutralising antibodies without causing disease.
- Unblinding
- Revealing which trial participants received the vaccine or placebo so that results can be analysed; expected by end of next year.
- Aedes mosquito
- The mosquito genus that primarily transmits the dengue virus to humans.
Practice questions
- Why does the existence of four dengue serotypes make vaccine development difficult, and how does a tetravalent single-dose candidate like DengiAll seek to overcome this?
- Discuss the role of indigenous vaccine development in strengthening India's response to endemic vector-borne diseases, using the DengiAll trial as an illustration.
- Official data show about 1.13 lakh dengue cases in India in 2025, yet experts warn of underreporting. Examine how surveillance gaps affect public health planning for vector-borne disease.
Grounded only in the source report — figures and dates are the source's, not inferred.